Hindustan Bio Sciences Ltd Stock Analysis

BSE: 532041 | NSE: | Pharmaceuticals & Drugs | Small Cap

BSE Share Price 09-Jun-2023 15:51
8.44 0.07 (0.84%)

DeciZen - Make an Informed Decision on Hind Bio Science

M-Cap below 100cr DeciZen not available

Hind Bio Science Price Chart

P/E Ratio ( SA) :
Market Cap :
8.6 Cr.
52-wk low :
52-wk high :
Bole Toh?

1. Is Hindustan Bio Sciences Ltd a good quality company?

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Hindustan Bio Sciences Ltd is a below average quality company.

2. Is Hindustan Bio Sciences Ltd undervalued or overvalued?

The key valuation ratios of Hindustan Bio Sciences Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.

3. Is Hindustan Bio Sciences Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Hindustan Bio Sciences Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of Hind Bio Science:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Hindustan Bio Sciences Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good

Value Creation

Value Creation Index Colour Code Guide

ROCE % -7.1%-9.9%-16.7%-10.6%-8.5%-49.1%2.6%1.7%-23.2%-16.7%-
Value Creation Index -1.5-1.7-2.2-1.8-1.6-4.5-0.8-0.9-2.7-2.2-

Growth Parameters

Growth Parameters Colour Code Guide

YoY Gr. Rt. %--42.2%-66.2%65.8%-19.8%2%245.6%-45.5%-46.9%-58.3%-
Adj EPS -0.7-0.9-1.4-0.7-0.5-
YoY Gr. Rt. %-NANANANANANA-27.3%-1237.5%NA-
BVPS (₹) 8.886.
Adj Net Profit -0.7-1-1.5-0.7-0.5-
Cash Flow from Ops. 0-0.5-0.30.5-0.2-0.2-
Debt/CF from Ops. 4.2-1.7-3.62.1-8-6.9-


CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales -21.7%-15.7%-50.6%-58.3%
Adj EPS NANA-265.7%NA
BVPS -23.8-28.8-28.5-39.4
Share Price 22.9% 54.8% 97.2% 128.7%

Key Financial Parameters

Performance Ratio Colour Code Guide

Return on Equity % -7.3-10.6-18.9-12.7-10.7-
Op. Profit Mgn % -16.6-38-184-9.8-46-227.93.87-90.3-116.44.9
Net Profit Mgn % -18.4-41.9-190.8-58.9-48.6-
Debt to Equity
Working Cap Days 7071,1923,1331,6732,0691,6534591,0011,5432,688233
Cash Conv. Cycle 8320138393119991052561322130

Recent Performance Summary

Return on Equity has increased versus last 3 years average to 1.20%

Sales growth is good in last 4 quarters at 18.86%

Sales growth has been subdued in last 3 years -50.57%

Debt to equity has increased versus last 3 years average to 2.75

Latest Financials - Hindustan Bio Sciences Ltd.

Standalone Consolidated
TTM EPS (₹) -0 -
TTM Sales (₹ Cr.) 0.9 -
BVPS (₹.) -7.3 -
Reserves (₹ Cr.) -10 -
P/BV -1.15 -
PE 0.00 -
From the Market
52 Week Low / High (₹) 3.23 / 11.73
All Time Low / High (₹) 0.10 / 106.65
Market Cap (₹ Cr.) 8.6
Equity (₹ Cr.) 2.1
Face Value (₹) 2
Industry PE 38.1

Management X-Ray of Hind Bio Science :

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *
* Pledged shares as % of Promoter's holding (%)

Event Update

Login/Register to view analysis.

Analyst's Notes

Key Ratios of Hind Bio Science

Adj EPS (Rs.)
Sales (Cr.)
ROE (%)
ROCE (%)


Hindustan Bio Sciences Ltd FAQs

Company share prices are keep on changing according to the market conditions. The closing price of Hind Bio Science on 09-Jun-2023 15:51 is : 8.44.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 09-Jun-2023 15:51 the market cap of Hind Bio Science stood at ₹ 8.58.
The latest PE ratio of Hind Bio Science as of 09-Jun-2023 15:51 is 0.00.
The latest PB ratio of Hind Bio Science as of 09-Jun-2023 15:51 is -1.15
The 52-week high of Hind Bio Science is ₹ 11.73 and the 52-week low is ₹ 3.23.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue / sales of Hind Bio Science is ₹ 0.92 ( Cr.) .

About Hindustan Bio Sciences Ltd

Hindustan Bio Sciences was incorporated in 1991. It is a limited company with a share capital of U.S $2.5 million based in Hyderabad, India. The people at the helm of affairs of the company are associated with pharmaceutical and healthcare sector for over two decades and are having penetrative knowledge of the needs of the sick. Hindustan Biosciences is a new entrant in the field of biopharmaceutical industry for providing quality healthcare for the treatment of life threatening diseases at affordable cost even to the lower income segment of Indian Society.

The company started its activities in the year 2001 and has been identifying potential recombinant DNA based biopharmaceutical products for marketing in India. The company has outsourced the manufacturing activity presently and the owned manufacturing facilities will be established at a latter stage. At present the company is setting up a research and development facility for developing the R DNA based biopharmaceuticals for human consumption. The company has finalized a technical consultation tie-up with CCMB (Centre for Cellular and Molecular Biology).


The company has obtained the approval of Genetic Engineering Approval Committee (GEAC) for import and marketing of Recombinant Human Erythropoietin manufactured by M/s. Shandong Kexing Bioproducts Co., Shandong, China. The protocol submitted by the company to conduct clinical trials has been approved by DCGI (Drug Controller General of India) and ethics committees of concerned Hospitals.

Hindustan Bio Sciences, engages in the import and marketing of recombinant deoxyribonucleic acid products for the treatment of life threatening diseases in India. It markets human erythropoietin manufactured by Shandong Kexing Bioproducts Co.

In 2001 the company entered into an agreement with CDSL, NSDL and Venture Capital & Corporate Investments Ltd (R&T agents) for dematerialization. In 2004 Hindustan Bio bagged GEAC nod recombinant human erythropoietin.

Read More Read Less
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login | Register Now